FY2026 Earnings Estimate for Novartis AG (NYSE:NVS) Issued By Zacks Research

Novartis AG (NYSE:NVS) – Research analysts at Zacks Research boosted their FY2026 EPS estimates for Novartis in a note issued to investors on Monday, April 22nd. Zacks Research analyst E. Bagri now forecasts that the company will post earnings per share of $8.47 for the year, up from their previous forecast of $8.36. The consensus estimate for Novartis’ current full-year earnings is $7.13 per share.

Several other research firms have also recently issued reports on NVS. BMO Capital Markets started coverage on shares of Novartis in a research note on Friday, February 23rd. They issued a “market perform” rating and a $114.00 target price for the company. Morgan Stanley assumed coverage on shares of Novartis in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $114.00 target price for the company. Three analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $114.00.

Novartis Trading Up 0.8 %

Shares of NYSE:NVS opened at $95.11 on Tuesday. The company has a market capitalization of $194.40 billion, a PE ratio of 13.25, a PEG ratio of 1.47 and a beta of 0.54. Novartis has a 12-month low of $92.19 and a 12-month high of $108.78. The business has a 50 day moving average of $97.98 and a two-hundred day moving average of $98.99. The company has a current ratio of 1.15, a quick ratio of 0.93 and a debt-to-equity ratio of 0.39.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, January 30th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.64 by ($0.11). The company had revenue of $11.42 billion for the quarter, compared to analysts’ expectations of $11.69 billion. Novartis had a net margin of 29.83% and a return on equity of 29.90%. During the same quarter in the previous year, the business posted $1.51 EPS.

Institutional Trading of Novartis

Several institutional investors and hedge funds have recently bought and sold shares of NVS. Murphy Middleton Hinkle & Parker Inc. raised its position in Novartis by 4.9% in the fourth quarter. Murphy Middleton Hinkle & Parker Inc. now owns 2,072 shares of the company’s stock valued at $209,000 after purchasing an additional 97 shares during the period. Pinnacle Bancorp Inc. increased its stake in Novartis by 2.8% during the fourth quarter. Pinnacle Bancorp Inc. now owns 3,641 shares of the company’s stock worth $368,000 after purchasing an additional 98 shares during the period. Optimum Investment Advisors grew its holdings in shares of Novartis by 23.3% in the fourth quarter. Optimum Investment Advisors now owns 530 shares of the company’s stock valued at $54,000 after purchasing an additional 100 shares in the last quarter. Chesley Taft & Associates LLC lifted its holdings in Novartis by 0.3% during the 4th quarter. Chesley Taft & Associates LLC now owns 33,062 shares of the company’s stock worth $3,338,000 after buying an additional 100 shares in the last quarter. Finally, Means Investment CO. Inc. boosted its position in Novartis by 1.3% in the 4th quarter. Means Investment CO. Inc. now owns 8,074 shares of the company’s stock valued at $815,000 after buying an additional 103 shares during the period. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Novartis Increases Dividend

The firm also recently announced an annual dividend, which was paid on Thursday, March 7th. Shareholders of record on Friday, March 8th were paid a dividend of $3.7772 per share. This is a boost from Novartis’s previous annual dividend of $3.47. The ex-dividend date of this dividend was Thursday, March 7th. This represents a yield of 3.1%. Novartis’s dividend payout ratio (DPR) is 33.84%.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.